French biopharmaceutical company NFL Biosciences (Euronext Growth Paris:ALNFL) said on Thursday that it has enrolled the first participant in its Phase 2 TONIC clinical study evaluating NFL-102 for smoking and nicotine cessation, marking the start of the trial's clinical phase.
The first participant was enrolled at the Eurofins Optimed clinical centre in Gières, France.
The multicentre, randomised, double-blind, placebo-controlled study will involve 310 smokers across France and assess NFL-102, a drug candidate designed to enhance neuroplasticity and address addiction. Its primary endpoint is four weeks of continuous abstinence, verified through urinary cotinine measurements.
The first stage, Part A, will involve 40 participants and evaluate three initial doses. An independent data monitoring committee and the company will review unblinded safety and efficacy data to determine which dose should be discontinued.
Initial results from Part A are expected in April 2027. The study will then progress to Part B, targeting an additional 270 participants across approximately 10 clinical centres, with further dose selection following the enrolment of the first 150 participants.
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial